Intravitreal injections are the highest-volume procedure in ophthalmology. The number of intravitreal injections (CPT 67028) submitted to the Medicare program—primarily by retinal specialists—grows each year and now exceeds 3 million.1 With volume comes innovation. We have seen significant advancements in retinal therapy from the early days of focal laser, photodynamic therapy (PDT), and Macugen to today’s successful anti-VEGF therapies for conditions like age-related macular degeneration (AMD), diabetic retinopathy, and macular edema. Moving forward, more effective therapies and longer treatment durations appear to be common goals,